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Abstract 
 
Neurodegenerative diseases including Alzheimer's disease are characterized by the build-up amyloid beta plaques 
resulting in non-regenerative nerve cell death. The nerve cell death causes limited brain activity, that triggers 
damage to cognitive and memory. Currently, no therapy for Alzheimer's disease is available and patients are treated 
for alleviating the symptoms. One of the suitable options could be antibody immunotherapy.The aim of this review 
to discuss antibody immunotherapy for the removal of amyloid beta plaques. The monoclonal antibodies bind 
amyloid beta plaques. This interaction leads to the activation of microglia in the nerve tissue and cleaning of 
deposits. The process of cleaning of amyloid deposits halts the brain damage, declines death of nerve tissue to 
maintain synaptic integrity of the brain. Immunotherapy leads a promising approach as a treatment option for 
Alzheimer’s disease because it targets the key mechanism by which nerve damage is being caused. However, with 
the limitation of monoclonal antibodies in order to cross the blood-brain barrier, the immunotherapy remains the key 
factor in making a viable treatment for patients with Alzheimer's disease. Although, there are methods been tested to 
increasethe absorption of monoclonal antibodies through the blood-brain barrier. 
 
Keywords: Alzheimer’s disease, beta-amyloid plaques, monoclonal antibody, transporters, Blood-brain barrier, 
Immunotherapy, Acetylcholine. 
 
Introduction 
 
 
Alzheimer Disease (AD) affects approximately 50 
million people worldwide in 2017 becoming one of the 
most expensive diseases to take care of [1]. It is 
estimated to cost $605 billion and the rate of growth 
for this disease will continually grow by 68% until 
2050 [1, 2]. This is largely due to the increased life 
expectancy with a fast-growing older population 
especially in China, India but also in economically 
developed countries like UK and USA, making chronic 
diseases like AD more prevalent [1, 3].The increased 
life expectancy offers a long time for the cells to age, 
causing the repair and recovery process becomes 
weaker. AD is a prevalent disease among the people 
aged over 65 although; early onset from the 40-50 
years has been reported [4].  
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There are two forms of AD: familial and sporadic. 
Familial AD is the early onset caused by genetic 
factors like APOE4 allele that have strong hereditary 
links within a family. Sporadic AD is late onset caused 
by a variety of genetic and environmental factors with 
ageing being the greatest risk factor [5, 6]. This essay 
focuses on the sporadic AD. 
Alzheimer Disease 
What is Sporadic AD? 
Sporadic AD is the most common form of AD making 
upto 97-98% of the cases [7].It is 
a neurodegenerative disease killing the nerve cells in 
the brain. Resulting in the loss of memory and 
confusion that later leads to dementia [6].  Any damage 
to the nerve cells is detrimental because nerve cells 
cannot regenerate. The lack of regenerative ability and 
damage to the nerve cells leads to the permanent loss 
of functional parts of the brain. The loss of brain 
function affects the physical and mental wellbeing of 
the aged person. Damaged nerves cells from the 
products of AD are located in the central nervous 
system present in the brain that is postmitotic [8]. 
Consequently, these cells cannot undergo cell division 
by mitosis to produce new cells. 
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How is AD caused? 
There are two main commonalities within the brain of 
AD patients seen in histology of brain tissue: the build-
upof amyloid-beta plaques and neurofibrillary 
tangles[9, 10].Both of these factors are toxic and 
damage the brain cells causing cell death, which leads 
to less connectivity within the brain. These factors also 
physically reduced the size of the temporal and parietal 
lobes of the brain, which affects auditory and visual 
processes; hence the common symptom of decline in 
the cognitive function is seen in AD patients [11]. 
Formation of Beta-Amyloid plaques 
 
1.  
Fig 1:Breakdown of the amyloid precursor protein (APP) into soluble products through the non-
amyloidogenic pathway andinsoluble amyloid beta (Aβ) aggregation through the amyloidogenic pathway [12]
Within nerve cells, there are amyloid 
precursor proteins (APP) that are extrinsic proteins 
required for repair of the cell membrane and binding to 
molecules outside the cells. APP is regularly broken 
down by protease enzymes: α-secretase and γ-
secretase, which hydrolyse peptide bonds to cut the 
APP into three smaller sections [9, 13].In AD, enzyme 
β-secretase is produced that cuts the APP in the 
incorrect position leading to the production of the 
amyloid beta peptide (Aβ), which is toxic to the nerve 
cells. The Aβ is able to leave the cell membrane 
attaching to other Aβ in the extracellular fluid of the 
brain and aggregating into long insoluble polymers in 
alpha helix shape stacked on top of each other 
producing amyloid beta plaques[9, 13].These plaques 
kill the cells by affecting the synaptic functions 
between the neurons by inhibiting proper release of 
neurotransmitter and slowing the action potential, 
which causes loss of normal function within the cells 
[14].Plaques also lead to inflammatory responses by 
the immune system causing macrophages, a type of 
white blood cell to attack nerve cells in the brain 
causing irreversible damage to the brain [15]. 
Therefore, it has become a target to inhibit the enzymes 
like β-secretase for slowing down the production of 
Aβ thereby reducing its effects.   
Formation of neurofibrillary tangles 
Another key feature is that the nerve cells have a 
cytoskeleton in the axon, which is a pathway of 
microtubules for the transport of nutrients made from 
tau proteins required for stabilising microtubules. Tau 
proteins during AD become hyper-phosphorylated by 
gaining phosphate group allowing the tau to clump 
together producing neurofibrillary tangles. The 
neurofibrillary tangles affect the synaptic 
communications between neurons causing cell death 
[9,10, 16]. 
Why is AD difficult to treat? 
AD is difficult to treat because the disease permanently 
damages the nerve cells so there is no way to restore 
previous functions unlike other parts of the body where 
transplants can occur. Aβ can aggregate with a rapid 
rate of growth through the brain affecting large areas, 
so it is not localized, therefore cannot be removed by 
surgery [17]. Drugs produced to get rid of Aβ plaques 
and neurofibrillary tangles cannot reach the brain in 
relevant concentration due to the blood-brain barrier. 
New drugs need to be produced with better permeation 
through this barrier to breakdown Aβ plaques to be 
effective against AD [18].Therefore, there is no 
permanent solution currently for decreasing the rate of 
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growth for AD other than palliative care measures to 
offer patients a better quality of life care.  
Current treatments used for AD 
What is acetylcholine? 
Acetylcholine (ACh) is a neurotransmitter released 
from synapses in normal action potentials found in 
regions like the hippocampus and temporal lobe, 
impairing areas of memory formation [19]. The 
cholinesterase enzyme breaks down the 
neurotransmitter into choline and ethanoic acid after a 
nervous impulse has passed through, to return ACh 
back to the pre-synaptic neuron[20]. 
What are the current treatments for AD? 
The most commonly prescribed drug for treating AD 
are cholinesterase inhibitors such as donepezil and 
galantamine for moderate to mild symptoms. As the 
person ages levels of ACh decreases [21]. The Aβ 
plaques interfere with synapses and the lowered levels 
of ACh, decreases communication between cells 
thereby decreasing short-term memory [22].The 
cholinesterase inhibitors inhibit cholinesterase enzyme 
competitively. The inhibitors have a similar molecular 
shape to ACh so it is able to bind to the active site of 
cholinesterase enzyme preventing the breakdown of 
ACh into its substrates. The neurotransmitter can stay 
longer exciting the postsynaptic neuron for more 
communication between the nerve cells before being 
broken down to decrease symptoms of AD. 
Cholinesterase inhibitors are able to manage the 
symptoms working in short-term but the body develops 
a tolerance to cholinesterase inhibitors needing larger 
doses for the same protective effects and fewer drugs 
become available to help the patient in later stages of 
AD [23]. 
Blood-brain barrier 
The blood-brain barrier (BBB) is a selectively 
permeable membrane, which separates molecules in the 
blood from the extracellular fluid in the brain. It allows 
the entry of specific molecules required by nerve cells 
like water, insulin, glucose and fatty acids by specific 
transporter proteins and prevents the entry of foreign 
molecules [24]. Crossing the BBB for producing a cure 
for AD remains the biggest challenge due to the highly 
controlled uptake. This is why so many new drugs 
developed fail, as they cannot enter in sufficient 
concentration [25].  
Structure of BBB 
The BBB is made up of endothelial cells in the 
capillary with tight junctions; these junctions are 
strands of protein that close the pores in capillaries [26, 
27, 28]. For capillaries found in other parts of the body, 
the pores allow tissue fluid to build up for the exchange 
of nutrients. In the brain, the build-up of tissue fluid 
can cause swellings and slow down the diffusion of 
essential molecules so tight junctions maintain normal 
function. There are also pericytes, which are cells that 
wrap around the capillary to maintain the structure and 
control properties like permeability and blood flow by 
vasoconstriction and vasodilation[29]. Astrocyte cells 
surround the brain side of the BBB for transport of 
molecules from the blood to the nerves cells [28, 
30].Therefore, drugs for the AD will be required to be 
engineered specifically to the BBB cells present and 
properties of such drugs should be dependent on these 
cells. 
Challenges to entry for drugs into BBB 
Molecular weight: Drug transport into BBB is difficult 
because of the tight junctions, which limit the 
molecular weight of drugs to approximately less than 
400 Daltons (Da) that are able to penetrate into the 
cells. Most clinical drugs have large molecular weights 
so they cannot penetrate into the cells through passive 
diffusion, so they require the use of transporter proteins 
present on the cell membrane for entry [31, 32]. 
Changing environment: The environment of the 
nerve cells and the BBB cells affects the structure of 
drugs. For instance, lipid solubility affects drug 
transport because high lipophilicity will allow the 
molecules to cross through the BBB. The drug’s 
hydrophobic characteristics allow it to cross many cell 
membranes but within the nerve cells, the aqueous 
environment requires the drug to be more hydrophilic 
to have an effect on the cells [31, 32]. 
Chemical structure: The chemical structure of the drug 
will be affected by changing the environment of the 
BBB cells so the molecular structure of the drug needs 
to be suitable for these conditions. This can be through 
having the correct proportion of hydrogen bonds for 
hydrophobic regions, as this will affect the water 
solubility to have an intended effect on the nerve cells 
[18, 32]. 
Efflux pumps: Efflux pumps present on the BBB have 
a useful purpose in removing harmful molecules from 
the barrier back into the blood preventing entry of the 
molecule to damage the nerve cells. However, this will 
limit the uptake of potential drugs so new drugs needed 
to aid in the treatment of neurodegenerative diseases 
could be made to mimic the nature of other absorbed 
molecules like glucose, which the efflux pumps are not 
likely to remove [31, 33].For example, P-glycoprotein 
is an efflux pump that has a broad range of substrates it 
has an important role in keeping out toxins, this 
prevents the entry of several drugs making them 
ineffective [33-35]. Therefore, the structure of the 
drugs needs to be designed in such a way as not to be 
similar to the substrates of efflux pumps for removal 
from the cells. 
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Immunotherapy 
What is immunotherapy? 
There are many difficulties for fully active drug for 
entry through the BBB due to its structure. There has 
been promising research using immunotherapy to 
target specific mechanism of AD because there is 
better uptake to cross the blood barrier and there is a 
better effect of the drug on the neurons. 
Immunotherapy is a treatment method using 
substances, which will lead to an immune response by 
causing the body immune system to destroy or inhibit 
the target. 
How does Aβ immunotherapy work? 
Immunotherapy being researched for AD involves the 
use of monoclonal antibodies against Aβ plaques as 
these have shown the greatest results of clearing in 
preclinical studies on mouse models, showing evidence 
for this to be further researched on humans. There have 
been over 9000 patients enrolled in immunotherapy 
research projects showing the need to explore more 
about the mechanism of AD that can be targeted for 
recovery of patients at different stages of the 
disease[15].Monoclonal antibodies (mAB) are 
produced by identical B cells from an original B parent 
cell through mitosis. mAB are highly specific in nature 
because the antigen-binding site is complementary to 
the antigen present on their target. This allows 
antibodies to bind to antigens present on Aβ plaques 
forming an antibody-antigen complex, which will “tag” 
the molecule for recognition and clearance by 
microglial cells within the brain [35]. Microglial cells 
are found on the nerve side of the BBB, they are 
macrophages of the brain tissue. They are to be able to 
move through the nerves to areas of damage to find 
substances causing inflammation [36, 37]. In a healthy 
brain, these cells remain dormant and have a role in 
detecting changes within the interstitial fluid, which 
surrounds the nerve cells and they assist in the 
development of the nervous system. These cells can 
detect the harmful proteins formed during 
neurodegenerative diseases, which cause inflammation 
of nerves producing active phagocytic microglial [37]. 
The microglial have been shown to carry out 
phagocytosis by engulfing and forming a vesicle 
around Aβ to digest it by lysozyme (a hydrolytic 
enzyme), decreasing the build-up of damaging plaques 
on the nerves [36, 37]. The phagocytic activity of 
microglial cells can be exploited through antibody 
treatments because the antibody allows better 
recognition of Aβ so there can be greater removal by 
the body’s immune system preventing plaque 
formation [15]. Thus, improving synaptic function and 
less cell death of neurons, which will lead to 
improvement in patient’s cognition and overall health. 
In AD, patients suffer from chronic pain requiring them 
to be on anti-inflammatory drugs because the Aβ 
plaque deposits cause inflammatory responses to the 
nerves, which leads to the activation of microglia 
[38].Additionally, in later stages of neurodegenerative 
diseases,there is disruption of the BBB causing it to 
become easily crossed by other types of immune cells 
like monocytes that attack the Aβ, which would not 
normally be present in the brain [37].This causes the 
release of an inflammatory cytokine, which are 
chemicals that attract more immune cells into the brain 
causing damage also to the healthy nerve [38].This 
could suggest that since both microglial and monocytes 
are part of the innate immune system, the infiltration 
by monocyte is a necessary process to assist the 
microglial with the removal of the damaging Aβ so 
there could be a fault present with the phagocytic 
ability of the microglial cells to remove Aβ.This is 
supported because studies have shown that blocking of 
Toll-like receptors (TLR) such as TLR4, which 
function in recognition of molecules by binding onto 
them, which have shown the failure of microglial for 
phagocytosis [36, 37]. 
Antibody uptake through BBB 
The disruption of the BBB caused in AD could be a 
possible beneficial property for drug development, as it 
will allow antibodies to easily cross. Antibodies found 
in the blood have a very low uptake into the astrocytes, 
only about 0.1-0.2% of antibodies are absorbed through 
the BBB to reach the nerves by passive diffusion [35]. 
The methods for larger uptake of antibodies across the 
BBB are carrier-mediated and receptor-mediated 
transport [35]. For uptake by these processes, 
antibodies have been conjugated. This is by binding 
antibody molecules with similar to the substrate of 
transporters for entry without the chemical 
characteristics of the antibodies like the hydrophobic or 
electrostatic charges affecting the transfer [24, 39]. 
Carrier-mediated transport: Carrier-mediated transport 
(CMT) is the movement of molecules using intrinsic 
transporter proteins to cross through cell membranes. 
This movement can be either by facilitated diffusion, 
which is a passive movement of polar molecules down 
a concentration gradient or active transport, which uses 
ATP for movement of polar molecules up 
concentration gradient in a single direction [18]. CMT 
allows entry of drugs with larger molecular weight by 
exploiting the substrates of transporters that have 
similar structural properties to the drug to be moved 
across the BBB after a successful collision with the 
transporter protein. Therefore, there is less effect of the 
tight junctions allowing drug with a molecular weight 
larger than 400 Da to cross [40].If the drug has been 
able to cross into the cell using intrinsic transporter 
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protein it will be less likely to be affected by efflux 
pumps because it is a required molecule by the brain 
due to the conjugated substrate on the antibody. 
Problems with using CMT are competitive or non-
competitive inhibition, which can slow down the 
uptake of important substrates of the carrier interfering 
with other mechanisms (18). For example, the Glucose 
transporter 1(GluT1) protein is an important glucose 
transporter into the brain and it has a high uptake rate 
required for cellular respiration [18]. In AD patients, 
the transporter works less efficiently so producing 
drugs that utilise GluT1 could inhibit the uptake of 
glucose needed in cellular respiration leading to cell 
death. However, effective use of carrier protein has 
been for the uptake of L-Dopa for the production of 
dopamine using the L-type amino acid 
transporter(LAT1) carrier, which is important in the 
uptake of a wide variety of amino acids into the brain 
required for protein synthesis [18, 41]. Dopamine is a 
neurotransmitter that can be used as effective 
treatments for Parkinson’s disease but dopamine 
cannot itself cross the BBB due to the hydrophilic 
properties. By forming L-Dopa, which is an optical 
isomer of dopamine there has been increased 
permeation of the drug through BBB because L-Dopa 
is a neutral amino acid able to successfully bind to 
LAT1 allowing entry into the brain without being 
affected by the hydrophilic properties [18, 42].Once 
crossing the BBB, L-dopa is decarboxylated by the 
enzyme to allow it to form dopamine neurotransmitter 
for effect [42]. Therefore, transporters like LAT1 could 
be used in the transport of antibodies by conjugating 
onto side chains of neutral amino acids to allow uptake 
then to be released into its active form by enzymes 
hydrolysing to remove side chains. This is also known 
as the Trojan horse approach [31]. 
Receptor-mediated transport: Receptor-mediated 
transport (RMT) uses the receptors on the cell 
membrane of the endothelial cells to bind onto. This 
allows the entry of molecules by endocytosis into the 
cells, by forming a vesicle around the molecules to 
allow the substance to enter the cell. This can only 
occur if the receptor is able to successfully bind to its 
substrate [40]. The drug will be released by exocytosis, 
which is the release of the substance from the cell by a 
vesicle fusing with the cell membrane to secrete out its 
content into the astrocytes to be distributed around the 
brain [40]. RMT at the BBB allows entry of larger 
molecules like iron and insulin so by conjugating 
antibodies with complementary proteins to the antigen 
receptors present on the cell membrane of the 
endothelial cell [24]. The drugs can enter by 
endocytosis decreasing the limitation of the tight 
junction for better permeation [40].This is a better 
method of transportation than CMT because the 
receptors, which the molecule has to attach, will only 
be present on that type of cell so the drug can reach 
a specified location without being absorbed into other 
cell membranes regardless of where the drug is 
administered into the body. However, challenges with 
RMT needs specific proteins, which forms a complex 
with the receptors for uptake and enzymes present 
within the cell, could break down the drug before it 
reaches nerve cells [18].This limits the successful 
uptake of the drug or could make the drug ineffective. 
Drug targets of AD: 
Aβ Plaque: Anti-Aβ antibodies can be successful in 
targeting Aβ plaques because there have been 
decreased levels of plaque [17]. This has been through 
the formation of the antibody-antigen complex to allow 
recognition of damaging Aβ, which has stimulated 
better receptor-mediated phagocytosis by microglial 
cells [23]. The anti- Aβ antibodies are able to enhance 
Phagocytosis due to the binding of the antibody with 
the Fc receptor, which initiates Phagocytosis on the 
surface of the microglial cells [15, 36].This suggests 
that Aβ could have a role in inhibiting microglial 
phagocytosis in AD patients so antibodies could be an 
effective method for activation of microglial to clear 
build-up of future deposits of plaque [36]. On a 
patient’s health, this could allow longer life expectancy 
because plaques are digested as they are produced so 
cognitive functions in patients could remain for longer 
periods.Production of anti-Aβ antibodies to target Aβ 
has shown results in multiple studies by using 
transferrin, which is a transporter protein regulating the 
delivery of iron into the nerve cells[43]. Transferrin 
protein has a separate transferrin receptor (TfR). 
Targeted binding of mAB with TfR is a fast process 
and it does not affect transferrin’s binding with iron 
transport, therefore it can allow uptake of mAB without 
damaging cell process involving iron or needing to 
compete with the uptake of iron. Additionally, TfR has 
a large presence on endothelial cells of the BBB 
making it a useful target for RMT from the blood to 
enter the brain [35, 40].However, mAB(s)have 
presented a challenge because most of the antibodies 
are transported across the BBB, but they are not well 
distributed through the brain [35]. This is due to 
antibodies having a high affinity to receptors that they 
bind to, which slows the distribution through the brain 
[43]. Lower concentrations of antibodies are present in 
the nerves to bind to Aβ. Lowering the affinity of 
antibodies to receptors using bispecific antibodies can 
solve this problem [44]. Bispecific antibodies have two 
different antigen-binding sites where each site can be 
made complementary to different antigens [45]. In this 
case, allowing one of the binding sites attaches to TfR 
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for entry to astrocytes and the other is able to attach to 
the Aβ on the neuron. The antibody is able to pass 
across the changing environments from endothelial 
cells to astrocytes. This has been supported by mice 
studies where the antibody concentration increased 
from 2 fold when using high-affinity antibodies to TfR 
to 6 fold when using low-affinity antibodies allowing 
better distribution around the brain [35]. In another 
study, bispecific antibodies have decreased the 
concentration of Aβ by 47% [44].Suggesting that 
bispecific antibody could be used as an additional drug 
with mAB together to decrease Aβ levels. 
Antibody inhibition of BACE1:β-secretase (BACE1) 
has been identified as the  main enzyme involved in the 
cleaving of APP to produce Aβ, BACE1 will form Aβ 
during its overproduction [9].Drugs produced, as 
inhibitors for BACE1 have been largely unsuccessful 
because of the inhibitor’s chemical properties like 
solubility and large molecular size causing lack of 
permeation through the BBB and lack of selectivity of 
the drug to attach to the enzyme [46, 47]. Anti-BACE1 
antibodies could be used for inhibition of BACE1 by 
binding to the enzyme and inhibiting it from cleaving 
APP to reduce the production of Aβ plaques, as there 
will be less enzyme activity [35]. The antibodies can 
use the carrier or receptor-mediated transport to travel 
across the BBB and the use of high-affinity antibodies 
can selectively target BACE1 [40]. BACE1 is highly 
present in the brain so this can allow more targeted 
drug action, as it will be specifically absorbed in these 
sites. This is beneficial as drugs that have low 
specificity could be diminished in concentrations by 
absorption into other cells.BACE1 cannot be 
completely inhibited because the enzyme is used in 
several other processes like myelination and synaptic 
functions, which could negatively affect other parts of 
the nervous system [48]. Selective inhibition of 
BACE1with antibodies could produce benefit by 
controlling excess levels of the enzyme [9]. Hence, 
there will be an overall decrease in concentrations of 
Aβ. Anti-BACE1 antibodies can be paired up with anti- 
Aβ antibodies (as discussed previously), which will 
decrease the production of new Aβ plaques and allow 
current plaques on nerve cells to be broken down by 
phagocytic microglial [35]. However, the results from 
inhibition of BACE1 have shown mixed responses in 
clinical studies because the decrease of Aβ is inversely 
proportional to the antibodies crossed into the brain 
[35]. This treatment method could be less viable as 
very high dosage is required to have enough anti-
BACE1 antibodies to decrease Aβ, which would not be 
possible on patients as the toxicity will be too high for 
treatment. 
Challenges & solutions associated with immune- 
therapy 
This essay has assumed on the antibodies being 
delivered through passive immunotherapy, which is 
injecting antibodies, not from the body that causes an 
immune response for targeting Aβ. There are problems 
associated with this approach because elderly patients 
have a weaker immune system so there could be a 
lower response by the body in the activation of 
microglial cells. On the other hand, there is potential 
for an autoimmune response, which is the immune cells 
attacking healthy nerve cells that cannot be controlled 
[49]. This could worsen the patient’s conditions but in 
current testing, there have been such no incidences 
seen in the patients [49].Passive immunotherapy will 
require further testing in clinical trials to find safety 
limits for the antibodies. A possible solution could be 
the use of active immunotherapy, which is releasing an 
antigen of Aβ into the system of the patient to cause 
immune cells to produce their own antibodies. Active 
immunotherapy could reduce the high cost of passive 
immunotherapy because lower dosages of Aβ antigens 
will be needed to make anti-Aβ antibodies [49]. 
Passive immunotherapy requires more repeated doses 
for long periods of time as the antibodies are quickly 
cleared from the body. Antibodies produced in active 
immunotherapy are longer lasting and will take longer 
to reach lower levels [15].The studies have used 
samples of patients with mild to moderate stages of 
AD, which has shown improvement in their health but 
not many late-stage AD studies have been carried out 
[22, 50]. This may be because the damage to the brain 
is too large to see an improvement and it could also be 
difficult to obtain late-stage AD patients to test 
immunotherapy up on. This infers that earlier detection 
of AD for immunotherapy will be more effective in 
slowing the progression of AD. Early diagnosis of AD 
allows symptoms to be more reversible, which makes 
them treatable as it can allow the body to adapt to 
antibodies for the elimination of plaque deposits before 
microglial cells become inhibited by Aβ [36].  
Prospective treatments 
Aducanumab antibody: Aducanumab is a current 
example of a successful monoclonal antibody against 
Aβ plaques that has reached phase three clinical trials 
on AD patients [53, 54]. This antibody has shown to be 
effective in reducing levels of Aβ in its 143 patients 
sample by increasing dosage levels for 12 months 
where a majority had lowered levels of Aβ [54]. At its 
highest doses, the antibody has been able to decrease 
levels of Aβ below the levels needed for a positive test, 
suggesting this could be highly useful as a potential 
treatment [54]. However, these studies have only 
focused on patients with early stages of AD therefore; 
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testing on later stages of AD is required to find safe 
concentrations for patients.  
Focused ultrasound therapy: Focused ultrasound 
therapy is a treatment method in its early stages of 
clinical trials on AD patients [50]. Ultrasound waves 
are the of the high frequency of sound waves above 
human hearing that can be focused at a fixed location 
forcing the BBB to open for a short time increasing 
permeability for drugs but it is also reversible to allow 
the BBB to close [39]. This opening allows the entry of 
anti-tau antibodies for treating neurofibrillary tangles. 
These studies have shown cognitive improvement 
when tested in memory tasks [50]. This treatment 
shows a possible non-invasive and safer drug delivery 
method for antibodies used in immunotherapy because 
ultrasound waves are non-ionising so it will not result 
in mutations of cells and drugs may require being less 
conjugated for uptake. Additionally, the ultrasound 
waves have shown to pass through the skull bone 
without requiring surgery to remove the bone and have 
shown not to damage surrounding neurons [55]. This 
has been evident by using the anti-Aβ antibody, BAM-
10, which has shown to decrease the number of plaque 
in 4 days after treatment on mouse models, showing 
this treatment having the potential to be viable for 
patients [50].  
 
Conclusion 
 
With the interest in preventing progression of AD 
rather than treating its symptoms, immunotherapy 
shows a useful therapeutic method by targeting the 
mechanism of AD that forms the toxic Aβ. Drug 
targets like Aβ plaques and BACE1 show potential for 
reducing Aβ. Antibodies can be better engineered to 
cross the BBB and their high selectivity in attaching to 
Aβ makes them useful for decreasing regions of the 
brain with the highest density of Aβ plaques. Current 
trails of the focused ultrasound and aducanumab 
further reinforce that antibodies targeting production of 
Aβ have shown results that antibodies are valuable 
drugs in improving cognition and nerve damage of 
patients but the absorption of antibodies into the brain 
tissue remains the biggest challenge in making 
monoclonal antibodies a suitable treatment method. 
However, anti-Aβ antibodies studies have proven to 
show results in mouse models but further clinical trials 
on patients are required to determine the effectiveness 
and decrease risks to patients like toxicity levels. 
Additionally, an important challenge is in identifying 
patients earlier with biomarkers for AD to allow 
antibodies to be more effective in preventing AD. 
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